Global Renal Biomarker Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Reports
  • Aug 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Renal Biomarker Market By Marker Type (Creatinine, Blood Urea Nitrogen (BUN), Cystatin C, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Others) Assay Platform Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzymatic Assay, Turbidimetric Immunoassay, Others) Application (Diagnosis and Disease Progression Monitoring, Research) Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa – Industry Trends and Forecast to 2026

Market Analysis Global Renal Biomarker Market

Global renal biomarker market is expected to rise by 2026 registering a substantial CAGR of 7.2% in the forecast period of 2019-2026. This evolution in the market can be attributed to the increase in research and development on new emerging drug delivery. The imminent market description contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Definition: Global Renal Biomarker Market

Renal biomarkers are generally comes in use of treatment of renal diseases. It is introduced in the renal function to examine the function of the renal system. These biomarkers are applicable into research and clinical areas. Clinical applications of Cystatin C, β-trace protein (BTP), neutrophil gelatinase-associated lipocalin Kidney injury molecule are observed in the patients. Increasing geriatric population as well as pediatric, suffering from renal disease accelerates the market growth.

Market Drivers

  • Increasing in incidence of kidney-related diseases growth in biomarker approval boosts the market growth
  • Increasing  geriatric patient as well as pediatric suffering from renal disease
  • Support from the governments are driving the market growth, by funding is boosting the market growth
  • Technological advancement in the field of genetics accelerate the market growth

Market Restraints

  • Market investigation for the global renal biomarker market, with area specific calculations and rivalry investigation on a global and county scale
  • Problem related to regulatory and reimbursement systems hinders the market growth

Segmentation: Global Renal Biomarker Market

By Marker Type

  • Creatinine
  • Blood Urea Nitrogen (BUN)
  • Cystatin C
  • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  • Others

    • N-Acetyl-β-D-Glucosaminidase (NAG)
    • Kidney Injury Molecule 1 (Kim1)
    • TIMP-2 (TIMP Metallopeptidase Inhibitor 2)
    • Liver-Type Fatty Acid-Binding Protein (L-FABP)
    • Interleukin-18 (IL-18)
    • Clusterin

By Assay Platform Type

  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Enzymatic Assay
  • Turbidimetric Immunoassay

    • Particle-Enhanced Turbidimetric Immunoassay (PETIA)

  • Others

    • Chemiluminescent Immunoassay (CLIA)
    • Fluorescence Immunoassay

By Application

  • Diagnosis and Disease Progression Monitoring
  • Research

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific

  • Middle East & Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In May 2019, Merck KGaA and Pfizer Inc., received FDA approval for Bavencio and Inlyta, which is usually used as combination for the renal diseases treatment. It is a kinase inhibitor, therefore, has an ability to treat cancer. This product approval leads to development of the market
  • In April 2019, Keytruda drug received approval from FDA for nephrology and oncology treatment. This new drug has the ability to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2,  hence can be used in the treatment of nephrological cancer and helped in the market growth

Competitive Analysis:

Global renal biomarker market is highly differentiated and the major companies have used various plans such as new product promotions, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes rehabilitation equipment market shares for Global, Europe, North America, Asia Pacific, and South America.

Key Market Competitors:

Few of the major competitors currently working in the global renal biomarker market are Abbott, F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Alere Inc., Siemens Healthcare, Randox Laboratories Ltd., Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., BIOPORTO A/S, Astute Medical, Inc., Randox Laboratories Ltd., Alere, Inc., BioMérieux SA, QUIAGEN, Bio-Rad Laboratories, Enzo Biochem, Inc., PerkinElmer, Inc. and others

Research Methodology: Global Renal Biomarker Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global renal biomarker market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART